RCPA Haem / classify it.

10,468 spaced-repetition flashcards aligned to the curriculum's learning-objective structure across the 223 LOs, with values-first cards because in haematology the number is the diagnosis. Card types include peripheral-blood-film morphology, flow cytometry markers, coagulation values, and transfusion thresholds. Each card ID is linked to an RCPA Haematology LO so cards surface alongside the relevant study note.

• Rebuilding per learning objective across malignant haematology, coagulation, red cell disorders, and transplantation
• Planned card types: WHO 2022 AML subtypes, IMWG myeloma criteria, DLBCL GCB/ABC, FLIPI; cytogenetics (t(15;17), t(8;21), inv(16), BCR-ABL1, del(17p), JAK2/CALR/MPL)
• Numerical threshold cards planned: ADAMTS13, ISTH DIC, Glucksberg, Sokal, 4T HIT
• One click from card to full study note when the deck lands

The RCPA Haematology Oral spans both parts of the exam. Part I Oral is station-based (10-20 min per station), with all candidates receiving the same structured questions; clinical vignettes with CBC, blood film description, coagulation studies, flow cytometry, cytogenetics, and molecular results. Part II Oral is a structured all-day Oral examination focused on haematology lab standards, research standards, and lab innovation and leadership. PRIMEX's viva simulator probes systematic interpretation, differential diagnosis, confirmatory investigations, and management at the depth both parts require.

• Integrated data vignettes: CBC + blood film + coagulation + flow cytometry + cytogenetics presented together
• High-yield scenarios: APL emergency (t(15;17) → ATRA immediately), AML with FLT3/NPM1, CLL with del(17p), HIT (day 5 post-cardiac surgery), TTP vs HUS, myeloma CRAB criteria
• Mechanism probes: "Why does del(17p) predict chemoimmunotherapy failure?", "What is the pathophysiology of TRALI?"
• Management with specific drug names, doses, and monitoring parameters

202 sourced study notes across the RCPA Haematology curriculum, one for every covered learning objective. Each follows a structured format: pathophysiology, classification (WHO 2022 where relevant), laboratory diagnosis, treatment with specific agents and thresholds, and exam focus. Cytogenetic and molecular data sit in clinical context, linking the mutation to the treatment decision.

• 202 study notes across the full RCPA Haematology curriculum, one per covered LO: malignant, coagulation, red cell, transplantation, laboratory
• WHO 2022 classification criteria with numerical thresholds in every relevant note
• Treatment notes: TKIs for CML, ibrutinib/venetoclax for CLL del(17p)/TP53, proteasome inhibitors for myeloma, ATRA for APL
• References to current ASH guidelines, Australian Haematology and Blood Cancer Group (AHBCG) guidelines, and landmark trials

223 LOs is a large curriculum to manage. PRIMEX's curriculum tab organises every LO by haematology domain (malignant, benign, coagulation, transfusion, laboratory, transplantation), with per-domain progress bars so you can see exactly which areas need another pass before the Part I Written, Dry Practical, and Oral components, and the Part II Oral.

• All 223 RCPA Haematology LOs mapped across domains
• Checkbox completion persisted to localStorage
• Per-domain progress bars showing coverage across all Part I and Part II components
• High-yield LOs flagged: APL emergency management, ADAMTS13 threshold, AML WHO 2022 defining abnormalities that override blast count